Gilead buys cell therapy partner Arcellx for up to $7.8bn Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

#Gilead #celltherapy #Arcellx #GileadSciences #celltherapies #cancer #oncology #CARTtherapy #multiplemyeloma #Anitocel #CARexpression #BCMAtarget #BCMAdirectedCARTs #relapsedmultiplemyeloma #refractorymultiplemyeloma #iMMagine1study #multiplemyelomapatients #BCMAbindertechnology
zurl.co/iWAbv

#Medsky🧪 #IDsky #microsky #pharmsky #oncosky #publichealth
Whole genome sequencing revealed that #Cryptococcusneoformans serotype A was found in CFS & #larynx of a patient undergoing treatment for #refractorymultiplemyeloma.

If your refractory Multiple Myeloma hasn’t responded to other approaches, you may qualify for a new clinical trial. Clinical trials may offer the opportunity for new options.

Find the right clinical trial for you: bit.ly/4113KH7

#MultipleMyeloma #ClinicalTrials #RefractoryMultipleMyeloma